Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Steady as we go "Longs" ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(62)
•••
Comment by WalkOverTheStrton Apr 08, 2021 7:56am
189 Views
Post# 32955263

RE:RE:RE:RE:Steady as we go "Longs" ...

RE:RE:RE:RE:Steady as we go "Longs" ...@Harvey I think Antibe is incredibly undervalued. To the point I question reality. Realistically IMO if PH3 succeeds the value of a full buyout should be $4b - $6b USD based on patent length  7.5 years of exclusivity in the US upon commercial launch, 10 years in EU and 8 years in Japan. If Antibe gets it act together and 352 returns positive human data in PH1 then the sky is the limit as it IMO validates the hs2 technology as a platform....
so in short yes I think Antibe is grossly undervalued, IMO analyst coverage are meaninless esp current ones as they were book runners and somehow the value gap needs to be closed (USA, Europe partner, PH3 start imo wont do it, but 352 start may help etc.). 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities